Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 14 studies | 20% ± 4% | |
oligodendrocyte | 12 studies | 30% ± 10% | |
endothelial cell | 9 studies | 28% ± 12% | |
microglial cell | 9 studies | 27% ± 9% | |
oligodendrocyte precursor cell | 9 studies | 29% ± 12% | |
astrocyte | 9 studies | 27% ± 10% | |
endothelial cell of lymphatic vessel | 8 studies | 25% ± 9% | |
GABAergic neuron | 7 studies | 39% ± 20% | |
glutamatergic neuron | 6 studies | 46% ± 23% | |
interneuron | 5 studies | 39% ± 20% | |
Mueller cell | 4 studies | 20% ± 2% | |
granule cell | 3 studies | 31% ± 14% | |
adventitial cell | 3 studies | 17% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 9 studies | 37% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1346.89 | 244 / 245 | 99% | 7.78 | 498 / 502 |
thymus | 100% | 1772.69 | 651 / 653 | 98% | 6.71 | 591 / 605 |
breast | 100% | 2915.78 | 459 / 459 | 95% | 10.60 | 1062 / 1118 |
adrenal gland | 99% | 1040.51 | 255 / 258 | 96% | 13.07 | 220 / 230 |
brain | 91% | 715.85 | 2406 / 2642 | 100% | 7.66 | 704 / 705 |
lung | 100% | 3012.99 | 577 / 578 | 90% | 6.00 | 1039 / 1155 |
skin | 96% | 4925.34 | 1734 / 1809 | 93% | 8.54 | 437 / 472 |
kidney | 90% | 733.28 | 80 / 89 | 96% | 9.07 | 861 / 901 |
ovary | 100% | 2101.56 | 180 / 180 | 83% | 3.96 | 356 / 430 |
intestine | 98% | 1499.37 | 943 / 966 | 70% | 3.70 | 370 / 527 |
esophagus | 92% | 1728.63 | 1325 / 1445 | 73% | 4.16 | 134 / 183 |
bladder | 100% | 2006.52 | 21 / 21 | 63% | 3.31 | 317 / 504 |
stomach | 87% | 1212.21 | 314 / 359 | 75% | 4.80 | 214 / 286 |
uterus | 100% | 2773.32 | 170 / 170 | 59% | 4.65 | 273 / 459 |
pancreas | 25% | 128.77 | 82 / 328 | 93% | 8.58 | 166 / 178 |
adipose | 100% | 2738.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3005.69 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 931.81 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 94% | 971.16 | 806 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 4.41 | 26 / 29 |
liver | 24% | 128.48 | 54 / 226 | 57% | 2.75 | 230 / 406 |
eye | 0% | 0 | 0 / 0 | 66% | 2.74 | 53 / 80 |
tonsil | 0% | 0 | 0 / 0 | 53% | 1.97 | 24 / 45 |
muscle | 38% | 218.67 | 307 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 10% | 49.45 | 94 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001955 | Biological process | blood vessel maturation |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_1904684 | Biological process | negative regulation of metalloendopeptidase activity |
GO_0030198 | Biological process | extracellular matrix organization |
GO_0090210 | Biological process | regulation of establishment of blood-brain barrier |
GO_0035115 | Biological process | embryonic forelimb morphogenesis |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_0045765 | Biological process | regulation of angiogenesis |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_1903053 | Biological process | regulation of extracellular matrix organization |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0007566 | Biological process | embryo implantation |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_1990909 | Cellular component | Wnt signalosome |
GO_0098552 | Cellular component | side of membrane |
GO_0017147 | Molecular function | Wnt-protein binding |
GO_0015026 | Molecular function | coreceptor activity |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0008191 | Molecular function | metalloendopeptidase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | RECK |
Protein name | Reversion-inducing cysteine-rich protein with Kazal motifs (hRECK) (Suppressor of tumorigenicity 15 protein) RECK protein |
Synonyms | ST15 |
Description | FUNCTION: Functions together with ADGRA2 to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B) . Plays a key role in Wnt7-specific responses: required for central nervous system (CNS) angiogenesis and blood-brain barrier regulation (By similarity). Acts as a Wnt7-specific coactivator of canonical Wnt signaling by decoding Wnt ligands: acts by interacting specifically with the disordered linker region of Wnt7, thereby conferring ligand selectivity for Wnt7 . ADGRA2 is then required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex . Also acts as a serine protease inhibitor: negatively regulates matrix metalloproteinase-9 (MMP9) by suppressing MMP9 secretion and by direct inhibition of its enzymatic activity . Also inhibits metalloproteinase activity of MMP2 and MMP14 (MT1-MMP) . . |
Accessions | O95980 Q6P9E2 ENST00000377966.4 |